Having trouble accessing articles? Reset your cache.

Nektar to wind down subsidiary after withdrawing opioid NDA

Nektar's decision to withdraw its NDA for oxycodegol will spell the end of its Inheris subsidiary, which it created last year ahead of the therapy's planned launch. The company will not invest

Read the full 329 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers